表紙
市場調查報告書
商品編碼
1078245

惡性間皮癌治療藥的全球市場(2022年∼2029年)

Global Malignant Mesothelioma Therapeutics Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球惡性間皮癌治療藥市場調查,提供市場概要,市場規模和預測,趨勢,成長要素及課題,客戶形勢,藥物類型·給藥途徑·終端用戶·各地區的分析,新企業簡介等資訊。

目錄

第1章 全球惡性間皮癌治療藥市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球惡性間皮癌治療藥市場:市場定義和概要

第3章 全球惡性間皮癌治療藥市場:摘要整理

  • 各藥物類型的市場明細
  • 各給藥途徑的市場明細
  • 各終端用戶的市場明細
  • 各地區的市場明細

第4章 全球惡性間皮癌治療藥市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球惡性間皮癌治療藥市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 法規分析

第6章 全球惡性間皮癌治療藥市場:COVID-19分析

  • 市場的COVID-19影響分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後或未來方案
  • COVID-19的價格變動
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球惡性間皮癌治療藥市場:各藥物類型

  • 簡介
    • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
    • 各藥物類型的市場魅力指數
  • Pemetrexed
    • 簡介
    • 市場規模分析(2020年∼2029年,及2021年∼2029年)
  • 順鉑(cisplatin)
  • 碳白金
  • Gemcitabine
  • Vinorelbine
  • 其他

第8章 全球惡性間皮癌治療藥市場:各給藥途徑

  • 簡介
    • 各給藥途徑的市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑的市場魅力指數
  • 口服
    • 簡介
    • 市場規模分析(2020年∼2029年,及2021年∼2029年)
  • 非口服

第9章 全球惡性間皮癌治療藥市場:各終端用戶

  • 簡介
    • 各終端用戶的市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶的市場魅力指數
  • 醫院
    • 簡介
    • 市場規模分析(2020年∼2029年,及2021年∼2029年)
  • 癌症中心
  • 其他

第10章 全球惡性間皮癌治療藥市場:各地區

  • 簡介
    • 各地區的市場規模分析(2020年∼2029年,及2021年∼2029年)
    • 各地區的市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑的市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑的市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要地區具體動態
    • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑的市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑的市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶的市場規模分析,及與前一年同期比較成長分析
    • 各國市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 各藥物類型的市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑的市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶的市場規模分析,及與前一年同期比較成長分析

第11章 全球惡性間皮癌治療藥市場:競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第12章 全球惡性間皮癌治療藥市場:企業簡介概要

  • Manusaktteva
    • 企業概要
    • 產品系列·種類
    • 主要亮點
    • 財務概要
  • Dr.Reddy Laboratories
  • Wellona Pharmaceuticals
  • LGM Pharmaceuticals
  • Pfizer
  • Ralington Pharmaceuticals
  • Calithera Biosciences
  • Polaris Pharmaceuticals
  • Ono Pharmaceuticals
  • Epizyme

第13章 全球惡性間皮癌治療藥市場:DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH5147

Market Overview

The global malignant mesothelioma therapeutics market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Malignant Mesothelioma is a rare and dangerous cancer that attacks the mesothelium, a thin lining surrounding the body's internal organs (pleurae, peritoneum, and pericardium). The mesothelium produces a lubricating fluid that protects the organs while also allowing them to move against each other. Shortness of breath, chest pain, and cough are all common symptoms. The symptoms can take anywhere from 35 to 50 years to appear. Malignant Mesothelioma can strike anyone at any age. However, it is more frequent in people over the age of 65. It is more frequent in men than women, with a 3:1 male to female ratio. Malignant Mesothelioma makes for 1% of all cancers around the globe.

Market Dynamics

Over the projected period, the market is expected to benefit from increased awareness of mesothelioma treatment and the availability of sophisticated treatments. Furthermore, the global market for malignant mesothelioma therapeutics is likely to be driven by asbestos in various products and sectors, which is a key cause of mesothelioma formation.

Increased awareness campaigns to diagnose and treat the disease at an earlier stage will drive the market growth

Malignant mesothelioma is becoming more common worldwide, necessitating increased awareness campaigns to diagnose and treat the disease at an earlier stage. Many groups are raising awareness about the condition and recommending asbestos-exposed employees get frequent screenings for malignant mesothelioma, which can help prevent the disease from progressing to advanced stages. This increased awareness is projected to impact market growth overall positively.

Furthermore, rising tobacco and smoking consumption propels the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.

In July 2019, Pfizer Inc. announced that its new medicine, RUXIENCE, has been approved by the United States Food and Drug Administration. This medication is a biosimilar version of Rituxan®. Patients with illnesses such as Granulomatosis with Polyangiitis (GPA), chronic lymphocytic leukemia (CLL), and non-lymphoma Hodgkin's (NHL) will be treated with this medicine. The company believes the medicine has significant development potential in improving the pricing and accessibility of essential cancer treatments.

Asbestos exposure is thought to cause malignant mesothelioma, and with global restrictions on asbestos use, mesothelioma instances are projected to decline soon. However, the number of malignant mesothelioma cases does not corroborate these assumptions.

According to Cancer Research UK figures, 1 in every 140 males and 1 in every 710 women is diagnosed with malignant mesothelioma. There has been an increase in men diagnosed with malignant mesothelioma. This aspect is driving sales growth in the Pemetrexed and combo category.

The preference for combination medicines over monotherapy is one of the key factors that positively influence the Pemetrexed and combination drug type sector. Combination therapies, such as chemotherapy combined with radiation, targeted antibody, cryotherapy, or other immunotherapies, are anticipated to expand the potential indications for various drugs. These combination therapies aim to improve survival rates significantly, as evidenced by limited clinical data compared to only surgeries or radiation therapies. Several companies have discovered that multiple pathways in tumor regulation are affected, and as a result, they seek to use combination therapy as a more effective method. These factors are likely to boost the malignant mesothelioma therapeutics market.

Long latency period for malignant mesothelioma is likely to hamper the market growth

However, a long latency period for malignant mesothelioma, a lack of disease-specific biomarkers in the early stages, and the development and approval of innovative devices for cancer treatment may slow the growth of the malignant mesothelioma therapeutics market throughout the projection period.

COVID-19 Impact Analysis

The global market for malignant mesothelioma therapeutics has benefited from the COVID-19 outbreak. With regard to the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.

According to 2020 Roche's quarterly reports, the company's global supply network for medicine and diagnostic tests remains intact, and pharmaceutical division sales increased by 7% over the previous year. The efficacy of oncology medications like ecentriq and Perjeta was credited with this rise. Other major players have noticed a similar trend in malignant mesothelioma medication sales. They saw an increase in global demand for oncology medications. During the global COVID-19 pandemic, market companies have responded to the rising demand for oncology medications.

Segment Analysis

The pemetrexed segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Pemetrexed is a new multitargeted antifolate that inhibits the purine and pyrimidine synthesis enzymes thymidylate synthase, dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Following the demonstration of the efficacy and safety of pemetrexed alone and in combination with cisplatin in treating mesothelioma, a randomized phase III trial in 456 patients with malignant pleural mesothelioma was conducted to compare single-agent cisplatin with pemetrexed plus cisplatin.

Furthermore, market growth is fueled by introducing new products into the market. For example, For example, in 2017, Boehringer Ingelheim began phase 3 of their double-blind, randomized phase 3 research of Nintedanib combined with Pemetrexed/Cisplatin, followed by the continuation Nintedanib monotherapy against the continuation of placebo monotherapy for mesothelioma treatment. These efforts by the market's main players are encouraging the expansion of the Pemetrexed and combo segment.

Geographical Analysis

North America region holds the largest market share of the global malignant mesothelioma therapeutics market

The market in the North American region is divided into three segments: the United States of America (USA), Canada, and Mexico. In 2021, the United States was a key participant in this region, accounting for more than half of the market. Because of increased awareness about risk factors and diagnostic procedures, the malignant mesothelioma market in North America is growing faster than in other areas.

Advanced healthcare infrastructure is expected to drive the growth of the malignant mesothelioma therapeutics market in North America. For instance, Sanofi revealed the results of ZynquistaTM's third phase. These trials are for persons with type 2 diabetes and were carried out at the InSynchrony clinical programme. The company announced that phase 3 will continue with no changes in the near future. The corporation has stated its desire to work with Lexicon to ensure the smooth transition of the research project.

Competitive Landscape

The malignant mesothelioma therapeutics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Manusaktteva, Dr.Reddy Laboratories, Wellona Pharmaceuticals, LGM Pharmaceuticals, Pfizer, RalingtonPharmaceuticals, Calithera Biosciences, Polaris Pharmaceuticals, Ono Pharmaceuticals, Epizyme, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the malignant mesothelioma therapeutics market globally. For instance, In July 2019,Astellas Pharma Inc. stated that it had formed a strategic alliance with Frequency Therapeutics Inc. Astellas will develop and market FX-322 outside of the United States under this agreement.

Dr. Reddy's Laboratories Ltd

Overview:

Dr. Reddy's Laboratories Ltd (DRL) is a multinational pharmaceutical firm committed to offering cheap and innovative medications to help people live healthier lives. Dr. Reddy offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics biosimilars and differentiated formulations through its three businesses - Pharmaceutical Services & Active Ingredients Global Generics and Proprietary Products. The company's key therapeutic areas of focus are gastrointestinal cardiovascular diabetology, oncology pain management, and dermatology. Dr. Reddy is present in markets all over the world. Its main markets include the United States, India, Russia, CIS countries, and Europe.

Product Portfolio:

Pemetrexed: Pemetrexed injection is used as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC) that has progressed to surrounding tissues or to other sections of the body, in combination with other chemotherapy drugs. Pemetrexed injection is also used as an ongoing treatment for NSCLC in persons who have already received specific chemotherapy medications and whose cancer has not deteriorated, as well as in people who could not be successfully treated with other chemotherapy treatments.

Why Purchase the Report?

Visualize the composition of the global malignant mesothelioma therapeutics market segmentation by drug type, route of administration, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global malignant mesothelioma therapeutics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global malignant mesothelioma therapeutics market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global malignant mesothelioma therapeutics market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Malignant Mesothelioma Therapeutics Market- By Drug Type

Pemetrexed

Cisplatin

Carbonplatin

Gemcitabine

Vinorelbine

Others

Global Malignant Mesothelioma Therapeutics Market- By Route of Administration

Oral

Parenteral

Global Malignant Mesothelioma Therapeutics Market- By End User

Hospitals

Cancer Centers

Others

Global Malignant Mesothelioma Therapeutics Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Malignant Mesothelioma Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Malignant Mesothelioma Therapeutics Market-Market Definition and Overview

3. Global Malignant Mesothelioma Therapeutics Market- Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market snippet By Route of Administration
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Malignant Mesothelioma Therapeutics Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness about malignant mesothelioma
      • 4.1.1.2. Increasing healthcare expenditure
    • 4.1.2. Restraints:
      • 4.1.2.1. Long latency period of malignant mesothelioma
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Malignant Mesothelioma Therapeutics Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Malignant Mesothelioma Therapeutics Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Malignant Mesothelioma Therapeutics Market- By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Pemetrexed*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Cisplatin
  • 7.4. Carbonplatin
  • 7.5. Gemcitabine
  • 7.6. Vinorelbine
  • 7.7. Others

8. Global Malignant Mesothelioma Therapeutics Market- By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Parenteral

9. Global Malignant Mesothelioma Therapeutics Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cancer Centers
  • 9.4. Others

10. Global Malignant Mesothelioma Therapeutics Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Malignant Mesothelioma Therapeutics Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Malignant Mesothelioma Therapeutics Market- Company Profiles

  • 12.1. Manusaktteva*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Dr.Reddy Laboratories
  • 12.3. Wellona Pharmaceuticals
  • 12.4. LGM Pharmaceuticals
  • 12.5. Pfizer
  • 12.6. Ralington Pharmaceuticals
  • 12.7. Calithera Biosciences
  • 12.8. Polaris Pharmaceuticals
  • 12.9. Ono Pharmaceuticals
  • 12.10. Epizyme

LIST NOT EXHAUSTIVE

13. Global Malignant Mesothelioma Therapeutics Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us